<DOC>
	<DOC>NCT00871767</DOC>
	<brief_summary>The aim of this study is to compare the blood levels achieved with a new formulation of AZD5672 to an existing formulation of AZD5672 used in previous studies</brief_summary>
	<brief_title>AZD5672 Bioavailability Study in Healthy Male and Female Subjects</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>N-(1-(3-(3,5-difluorophenyl)-3-(4-methanesulfonylphenyl)propyl)piperidin-4-yl)-N-ethyl-2-(4-methanesulfonylphenyl)acetamide</mesh_term>
	<criteria>Provision of informed consent prior to any studyspecific procedures BMI between 18 and 30 kg/m2 Medical and surgical history and physical examination without any clinically significant findings Non smokers or past smokers who have stopped smoking within the last 6 months. History of clinically significant cardio or cerebrovascular, pulmonary, renal, hepatic, neurological, mental or gastrointestinal disorder or any other major disorder that may interfere with the objectives of the study, as judged by the Investigator Clinically significant illness as judged by the Investigator, within two weeks before the first administration of investigational product. Female subjects who have a positive pregnancy test or who are pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>AZD5672</keyword>
	<keyword>relative bioavailability</keyword>
	<keyword>rheumatoid arthritis (RA)</keyword>
</DOC>